Pylarify radiopharmaceutical isotopes for prostate cancer patients
Ended Purchase Order Awarded Last action
- Contract number
- 36C24222P0240
- Awardee
-
Sofie CO. UEI JV1AHJHGUGG3 Part of Sofie Biosciences, Inc.
- Awarding agency
-
Veterans Integrated Service Network 2
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $1,372,920
Award facts
- Opportunity
-
- 6505--Intent to sole source Pylarify PSMA PET prostate cancer imaging agent- VISN 2 Down State Special Notice · 36C24222Q0053 · Posted Oct 14, 2021
- Contract value 100% obligated
- $1,372,919.70 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed · 1 offer Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- Sterling, VA, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$270,600 | |
| Supplemental Agreement for work within scope | -$48,944 | |
| Supplemental Agreement for work within scope | $13,984 | |
| Supplemental Agreement for work within scope | $77,312 | |
| Supplemental Agreement for work within scope | $69,920 | |
| Supplemental Agreement for work within scope | $83,904 | |
| Other Administrative Action | $349,600 | |
| Supplemental Agreement for work within scope | $83,904 | |
| Original award | $1,013,840 |
About this award
The Department of Veterans Affairs Veterans Health Administration awarded a $1.37 million firm fixed price purchase order to Sofie CO., doing business as Sofie, for the delivery of Pylarify radiopharmaceutical isotopes for prostate cancer patients. The contract supports the Special Notice published by VA Network Contracting Office 2 announcing sole source award to Progenics Pharmaceuticals, Inc. through their distributor Sofie. The award aims to provide Pylarify, a prostate-specific membrane antigen positron emission tomography imaging agent, to VA medical facilities in New York, New Jersey, and the Bronx for detecting prostate cancer metastasis or recurrence. Performance will take place in Sterling, Virginia over one year. Parent company Sofie Biosciences, Inc. is the prime contractor, with no mention of major subcontractors. This contract furthers the VA's mission to serve veterans through the Veterans Health Administration's cancer care programs.
Quick answers
Who was awarded contract 36C24222P0240?
36C24222P0240 was awarded to Sofie CO. by Veterans Integrated Service Network 2 (Veterans Health Administration) on December 15, 2021.
How much is contract 36C24222P0240 worth?
The government has obligated $1,372,920 on 36C24222P0240.
Was contract 36C24222P0240 competed?
The extent of competition for 36C24222P0240 was not competed. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award